Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1991-01

AUTHORS

S Nicholson, J Richard, C Sainsbury, P Halcrow, P Kelly, B Angus, C Wright, J Henry, JR Farndon, AL Harris

ABSTRACT

More accurate criteria are required for the selection of patients with node-negative breast cancer for systemic adjuvant therapy. Expression of epidermal growth factor receptor (EGFr) has been shown previously to be inversely related to oestrogen receptor (ER) in patients with operable breast cancer and to be associated with a poorer prognosis. Analysis of EGFr and ER was performed on tumour samples from 231 patients with operable breast cancer followed for up to 6 years after surgery. The median duration of follow-up in patients still alive at the time of analysis was 45 months. Thirty-five percent of patients (82) had tumours with greater than 10 fmol mg-1 I125-EGF binding (EGFr+) and 47% (109) and cystolic ER concentrations greater than 5 fmol mg-1 (ER+), with a marked inverse relationship between EGFr and ER (P less than 0.00001). In a univariate analysis EGFr was second only to axillary node status as a prognostic marker for all patients both in terms of relapse-free and overall survival (P less than 0.001, log rank). For patients with histologically negative axillary nodes EGFr was superior to ER in predicting relapse and survival (P less than 0.01 and P less than 0.005 respectively compared to P less than 0.1 and P less than 0.1, log rank). In a multivariate (Cox model) analysis only EGFr, out of EGFr, ER, size and grade, was predictive for either relapse-free or overall survival for patients with node-negative disease (P = 0.05 and P = 0.026 respectively). EGFr has been shown to be a marker of poor prognosis for patients with node-negative breast cancer. Since patients with EGFr+ tumours are unlikely to respond to hormone therapy it may be possible to select them for trials of systemic adjuvant chemotherapy. More... »

PAGES

146-150

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1991.30

DOI

http://dx.doi.org/10.1038/bjc.1991.30

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1049359708

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1846551


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Intraductal, Noninfiltrating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multivariate Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Bristol Royal Infirmary, W. Yorks, UK", 
          "id": "http://www.grid.ac/institutes/grid.418482.3", 
          "name": [
            "Department of Surgery, Bristol Royal Infirmary, W. Yorks, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nicholson", 
        "givenName": "S", 
        "id": "sg:person.01351112173.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351112173.34"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Richard", 
        "givenName": "J", 
        "id": "sg:person.014676023077.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014676023077.66"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Sainsbury", 
        "givenName": "C", 
        "id": "sg:person.015473403477.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015473403477.16"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Halcrow", 
        "givenName": "P", 
        "id": "sg:person.01006374733.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006374733.32"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Kelly", 
        "givenName": "P", 
        "id": "sg:person.01012463077.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012463077.88"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Angus", 
        "givenName": "B", 
        "id": "sg:person.01074006611.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074006611.11"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Wright", 
        "givenName": "C", 
        "id": "sg:person.012562656552.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012562656552.35"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Henry", 
        "givenName": "J", 
        "id": "sg:person.010251066422.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010251066422.07"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Farndon", 
        "givenName": "JR", 
        "id": "sg:person.01144734362.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144734362.17"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Harris", 
        "givenName": "AL", 
        "id": "sg:person.01151433574.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151433574.57"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1981.8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045272747", 
          "https://doi.org/10.1038/bjc.1981.8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1988.315", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014966882", 
          "https://doi.org/10.1038/bjc.1988.315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1977.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027080276", 
          "https://doi.org/10.1038/bjc.1977.1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01806484", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019243118", 
          "https://doi.org/10.1007/bf01806484"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1982.106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013337126", 
          "https://doi.org/10.1038/bjc.1982.106"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-01", 
    "datePublishedReg": "1991-01-01", 
    "description": "More accurate criteria are required for the selection of patients with node-negative breast cancer for systemic adjuvant therapy. Expression of epidermal growth factor receptor (EGFr) has been shown previously to be inversely related to oestrogen receptor (ER) in patients with operable breast cancer and to be associated with a poorer prognosis. Analysis of EGFr and ER was performed on tumour samples from 231 patients with operable breast cancer followed for up to 6 years after surgery. The median duration of follow-up in patients still alive at the time of analysis was 45 months. Thirty-five percent of patients (82) had tumours with greater than 10 fmol mg-1 I125-EGF binding (EGFr+) and 47% (109) and cystolic ER concentrations greater than 5 fmol mg-1 (ER+), with a marked inverse relationship between EGFr and ER (P less than 0.00001). In a univariate analysis EGFr was second only to axillary node status as a prognostic marker for all patients both in terms of relapse-free and overall survival (P less than 0.001, log rank). For patients with histologically negative axillary nodes EGFr was superior to ER in predicting relapse and survival (P less than 0.01 and P less than 0.005 respectively compared to P less than 0.1 and P less than 0.1, log rank). In a multivariate (Cox model) analysis only EGFr, out of EGFr, ER, size and grade, was predictive for either relapse-free or overall survival for patients with node-negative disease (P = 0.05 and P = 0.026 respectively). EGFr has been shown to be a marker of poor prognosis for patients with node-negative breast cancer. Since patients with EGFr+ tumours are unlikely to respond to hormone therapy it may be possible to select them for trials of systemic adjuvant chemotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.1991.30", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "63"
      }
    ], 
    "keywords": [
      "operable breast cancer", 
      "epidermal growth factor receptor", 
      "node-negative breast cancer", 
      "breast cancer", 
      "growth factor receptor", 
      "overall survival", 
      "poor prognosis", 
      "systemic adjuvant therapy", 
      "systemic adjuvant chemotherapy", 
      "percent of patients", 
      "axillary node status", 
      "node-negative disease", 
      "factor receptor", 
      "node-negative subgroup", 
      "selection of patients", 
      "marked inverse relationship", 
      "adjuvant chemotherapy", 
      "adjuvant therapy", 
      "median duration", 
      "hormone therapy", 
      "year follow", 
      "node status", 
      "negative subgroup", 
      "prognostic marker", 
      "estrogen receptor", 
      "patients", 
      "multivariate analysis", 
      "Analysis of EGFR", 
      "time of analysis", 
      "cancer", 
      "tumor samples", 
      "receptors", 
      "prognosis", 
      "survival", 
      "therapy", 
      "tumors", 
      "inverse relationship", 
      "markers", 
      "accurate criteria", 
      "relapse", 
      "chemotherapy", 
      "surgery", 
      "ER", 
      "follow", 
      "disease", 
      "trials", 
      "months", 
      "subgroups", 
      "duration", 
      "status", 
      "percent", 
      "grade", 
      "expression", 
      "Er concentration", 
      "more accurate criteria", 
      "years", 
      "criteria", 
      "analysis", 
      "study", 
      "binding", 
      "concentration", 
      "samples", 
      "relationship", 
      "time", 
      "results", 
      "emphasis", 
      "selection", 
      "size", 
      "terms"
    ], 
    "name": "Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup", 
    "pagination": "146-150", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1049359708"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1991.30"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1846551"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1991.30", 
      "https://app.dimensions.ai/details/publication/pub.1049359708"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_243.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.1991.30"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.30'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.30'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.30'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.30'


 

This table displays all metadata directly associated to this object as RDF triples.

249 TRIPLES      22 PREDICATES      112 URIs      99 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1991.30 schema:about N07a00ecde4bc4e7d99aa9f5e9b110b0a
2 N18b6c6be7a5b4d3fb9374bfa15b2e18b
3 N2962e1b6f19e4c4bb51ff53780c620f8
4 N4caa94eaa4de464f8ffd639084afecf8
5 N5902449f08774c97bc43c00a75ee45c8
6 N6292b698039541fb9e5f1572bb99b4cd
7 N6dbe7848bc7b4771b4b1bb628024fd6b
8 N82c2d1f5c7c046d78a221d7d2f3a960c
9 N9d7085e3295349f59c18ad211addf21e
10 Nf804a1ae9d1a43f38547786e249e56cc
11 Nfc34019ae5e74e68b20379d455731dd3
12 anzsrc-for:11
13 anzsrc-for:1112
14 schema:author Nd0847243e9924aea8247978d589e7b8a
15 schema:citation sg:pub.10.1007/bf01806484
16 sg:pub.10.1038/bjc.1977.1
17 sg:pub.10.1038/bjc.1981.8
18 sg:pub.10.1038/bjc.1982.106
19 sg:pub.10.1038/bjc.1988.315
20 schema:datePublished 1991-01
21 schema:datePublishedReg 1991-01-01
22 schema:description More accurate criteria are required for the selection of patients with node-negative breast cancer for systemic adjuvant therapy. Expression of epidermal growth factor receptor (EGFr) has been shown previously to be inversely related to oestrogen receptor (ER) in patients with operable breast cancer and to be associated with a poorer prognosis. Analysis of EGFr and ER was performed on tumour samples from 231 patients with operable breast cancer followed for up to 6 years after surgery. The median duration of follow-up in patients still alive at the time of analysis was 45 months. Thirty-five percent of patients (82) had tumours with greater than 10 fmol mg-1 I125-EGF binding (EGFr+) and 47% (109) and cystolic ER concentrations greater than 5 fmol mg-1 (ER+), with a marked inverse relationship between EGFr and ER (P less than 0.00001). In a univariate analysis EGFr was second only to axillary node status as a prognostic marker for all patients both in terms of relapse-free and overall survival (P less than 0.001, log rank). For patients with histologically negative axillary nodes EGFr was superior to ER in predicting relapse and survival (P less than 0.01 and P less than 0.005 respectively compared to P less than 0.1 and P less than 0.1, log rank). In a multivariate (Cox model) analysis only EGFr, out of EGFr, ER, size and grade, was predictive for either relapse-free or overall survival for patients with node-negative disease (P = 0.05 and P = 0.026 respectively). EGFr has been shown to be a marker of poor prognosis for patients with node-negative breast cancer. Since patients with EGFr+ tumours are unlikely to respond to hormone therapy it may be possible to select them for trials of systemic adjuvant chemotherapy.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf Nc60305642b5e49b4a1598e5ec926fba0
27 Nf7e9b7c7ec0d4ba885ef3a0d9a4331c4
28 sg:journal.1017082
29 schema:keywords Analysis of EGFR
30 ER
31 Er concentration
32 accurate criteria
33 adjuvant chemotherapy
34 adjuvant therapy
35 analysis
36 axillary node status
37 binding
38 breast cancer
39 cancer
40 chemotherapy
41 concentration
42 criteria
43 disease
44 duration
45 emphasis
46 epidermal growth factor receptor
47 estrogen receptor
48 expression
49 factor receptor
50 follow
51 grade
52 growth factor receptor
53 hormone therapy
54 inverse relationship
55 marked inverse relationship
56 markers
57 median duration
58 months
59 more accurate criteria
60 multivariate analysis
61 negative subgroup
62 node status
63 node-negative breast cancer
64 node-negative disease
65 node-negative subgroup
66 operable breast cancer
67 overall survival
68 patients
69 percent
70 percent of patients
71 poor prognosis
72 prognosis
73 prognostic marker
74 receptors
75 relapse
76 relationship
77 results
78 samples
79 selection
80 selection of patients
81 size
82 status
83 study
84 subgroups
85 surgery
86 survival
87 systemic adjuvant chemotherapy
88 systemic adjuvant therapy
89 terms
90 therapy
91 time
92 time of analysis
93 trials
94 tumor samples
95 tumors
96 year follow
97 years
98 schema:name Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup
99 schema:pagination 146-150
100 schema:productId N681b5b13755b49f4a539bf0c1de3371a
101 N8ca8e7754a434ebaa78a5a6e5e9d9e78
102 Nfe378d4b762c4e699fe4dbe62033e7d2
103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049359708
104 https://doi.org/10.1038/bjc.1991.30
105 schema:sdDatePublished 2022-05-20T07:19
106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
107 schema:sdPublisher N24c0971aa59f439ab2f2095607f97ed3
108 schema:url https://doi.org/10.1038/bjc.1991.30
109 sgo:license sg:explorer/license/
110 sgo:sdDataset articles
111 rdf:type schema:ScholarlyArticle
112 N07a00ecde4bc4e7d99aa9f5e9b110b0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Female
114 rdf:type schema:DefinedTerm
115 N18b6c6be7a5b4d3fb9374bfa15b2e18b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Follow-Up Studies
117 rdf:type schema:DefinedTerm
118 N24c0971aa59f439ab2f2095607f97ed3 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 N2962e1b6f19e4c4bb51ff53780c620f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Time Factors
122 rdf:type schema:DefinedTerm
123 N419999efc4994b19b91e9d37e63b6078 rdf:first sg:person.01012463077.88
124 rdf:rest N9565b0bad732474081d591ef2f04b89a
125 N4caa94eaa4de464f8ffd639084afecf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Humans
127 rdf:type schema:DefinedTerm
128 N5902449f08774c97bc43c00a75ee45c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Middle Aged
130 rdf:type schema:DefinedTerm
131 N60062855a4524cab9d98c58ba44415ef rdf:first sg:person.01151433574.57
132 rdf:rest rdf:nil
133 N6292b698039541fb9e5f1572bb99b4cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name ErbB Receptors
135 rdf:type schema:DefinedTerm
136 N681b5b13755b49f4a539bf0c1de3371a schema:name pubmed_id
137 schema:value 1846551
138 rdf:type schema:PropertyValue
139 N6dbe7848bc7b4771b4b1bb628024fd6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Multivariate Analysis
141 rdf:type schema:DefinedTerm
142 N7acb200e698e4c9e824b603bd7975f0e rdf:first sg:person.014676023077.66
143 rdf:rest N83748d9379f447ada5c05664d5502179
144 N82c2d1f5c7c046d78a221d7d2f3a960c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Prognosis
146 rdf:type schema:DefinedTerm
147 N83748d9379f447ada5c05664d5502179 rdf:first sg:person.015473403477.16
148 rdf:rest N9817335bb4a84a60b257a7b9cacf802d
149 N8ca8e7754a434ebaa78a5a6e5e9d9e78 schema:name doi
150 schema:value 10.1038/bjc.1991.30
151 rdf:type schema:PropertyValue
152 N9565b0bad732474081d591ef2f04b89a rdf:first sg:person.01074006611.11
153 rdf:rest Nd78ba7f1f7c94f61bf024f9c27628d24
154 N9817335bb4a84a60b257a7b9cacf802d rdf:first sg:person.01006374733.32
155 rdf:rest N419999efc4994b19b91e9d37e63b6078
156 N9d7085e3295349f59c18ad211addf21e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Carcinoma, Intraductal, Noninfiltrating
158 rdf:type schema:DefinedTerm
159 Nc60305642b5e49b4a1598e5ec926fba0 schema:volumeNumber 63
160 rdf:type schema:PublicationVolume
161 Nd0847243e9924aea8247978d589e7b8a rdf:first sg:person.01351112173.34
162 rdf:rest N7acb200e698e4c9e824b603bd7975f0e
163 Nd78ba7f1f7c94f61bf024f9c27628d24 rdf:first sg:person.012562656552.35
164 rdf:rest Nf72687cf30a0498da5c8bd57b405e9d7
165 Nf6ec99545c7f4997979bc797fff3c8d9 rdf:first sg:person.01144734362.17
166 rdf:rest N60062855a4524cab9d98c58ba44415ef
167 Nf72687cf30a0498da5c8bd57b405e9d7 rdf:first sg:person.010251066422.07
168 rdf:rest Nf6ec99545c7f4997979bc797fff3c8d9
169 Nf7e9b7c7ec0d4ba885ef3a0d9a4331c4 schema:issueNumber 1
170 rdf:type schema:PublicationIssue
171 Nf804a1ae9d1a43f38547786e249e56cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Breast Neoplasms
173 rdf:type schema:DefinedTerm
174 Nfc34019ae5e74e68b20379d455731dd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Prospective Studies
176 rdf:type schema:DefinedTerm
177 Nfe378d4b762c4e699fe4dbe62033e7d2 schema:name dimensions_id
178 schema:value pub.1049359708
179 rdf:type schema:PropertyValue
180 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
181 schema:name Medical and Health Sciences
182 rdf:type schema:DefinedTerm
183 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
184 schema:name Oncology and Carcinogenesis
185 rdf:type schema:DefinedTerm
186 sg:journal.1017082 schema:issn 0007-0920
187 1532-1827
188 schema:name British Journal of Cancer
189 schema:publisher Springer Nature
190 rdf:type schema:Periodical
191 sg:person.01006374733.32 schema:familyName Halcrow
192 schema:givenName P
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006374733.32
194 rdf:type schema:Person
195 sg:person.01012463077.88 schema:familyName Kelly
196 schema:givenName P
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012463077.88
198 rdf:type schema:Person
199 sg:person.010251066422.07 schema:familyName Henry
200 schema:givenName J
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010251066422.07
202 rdf:type schema:Person
203 sg:person.01074006611.11 schema:familyName Angus
204 schema:givenName B
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074006611.11
206 rdf:type schema:Person
207 sg:person.01144734362.17 schema:familyName Farndon
208 schema:givenName JR
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144734362.17
210 rdf:type schema:Person
211 sg:person.01151433574.57 schema:familyName Harris
212 schema:givenName AL
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151433574.57
214 rdf:type schema:Person
215 sg:person.012562656552.35 schema:familyName Wright
216 schema:givenName C
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012562656552.35
218 rdf:type schema:Person
219 sg:person.01351112173.34 schema:affiliation grid-institutes:grid.418482.3
220 schema:familyName Nicholson
221 schema:givenName S
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351112173.34
223 rdf:type schema:Person
224 sg:person.014676023077.66 schema:familyName Richard
225 schema:givenName J
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014676023077.66
227 rdf:type schema:Person
228 sg:person.015473403477.16 schema:familyName Sainsbury
229 schema:givenName C
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015473403477.16
231 rdf:type schema:Person
232 sg:pub.10.1007/bf01806484 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019243118
233 https://doi.org/10.1007/bf01806484
234 rdf:type schema:CreativeWork
235 sg:pub.10.1038/bjc.1977.1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027080276
236 https://doi.org/10.1038/bjc.1977.1
237 rdf:type schema:CreativeWork
238 sg:pub.10.1038/bjc.1981.8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045272747
239 https://doi.org/10.1038/bjc.1981.8
240 rdf:type schema:CreativeWork
241 sg:pub.10.1038/bjc.1982.106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013337126
242 https://doi.org/10.1038/bjc.1982.106
243 rdf:type schema:CreativeWork
244 sg:pub.10.1038/bjc.1988.315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014966882
245 https://doi.org/10.1038/bjc.1988.315
246 rdf:type schema:CreativeWork
247 grid-institutes:grid.418482.3 schema:alternateName Department of Surgery, Bristol Royal Infirmary, W. Yorks, UK
248 schema:name Department of Surgery, Bristol Royal Infirmary, W. Yorks, UK
249 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...